SUBSCRIBE
SUBSCRIBE

Immunic Therapeutics

IN THE PRESS
Business
Immunic, Inc. Reports First Quarter 2024 Financial Results and Provides Corporate Update
May 8, 2024
 · 
14 min read
Pharm Country
Immunic to Participate in Investor and Scientific Conferences in May 2024
May 6, 2024
 · 
6 min read
Business
Immunic, Inc. to Announce Financial Results for the First Quarter Ended March 31, 2024, and Provide Corporate Update
May 1, 2024
 · 
5 min read
Drug Development
Immunic Announces Publication of Extended Data From Phase 2 EMPhASIS Trial of Vidofludimus Calcium in Relapsing-Remitting Multiple Sclerosis in the Peer Reviewed Journal, Neurology® Neuroimmunology & Neuroinflammation
April 30, 2024
 · 
10 min read
Pharm Country
Immunic to Host MS R&D Day and Participate in Investor Conferences in April 2024
April 4, 2024
 · 
5 min read
Pharm Country
Immunic Receives Notice of Allowance for Composition-of-Matter Patent of a Specific Polymorph of Vidofludimus Calcium in the United States
March 20, 2024
 · 
8 min read
Pharm Country
Immunic to Participate in Investor and Scientific Conferences in March 2024
March 7, 2024
 · 
6 min read
Pharm Country
Immunic, Inc. to Announce Financial Results for the Year Ended December 31, 2023, and Provide Corporate Update
February 15, 2024
 · 
5 min read
Pharm Country
Immunic to Participate in Investor and Scientific Conferences in February
February 1, 2024
 · 
5 min read
Pharm Country
Immunic, Inc. Announces Private Placement of up to $240 Million
January 5, 2024
 · 
8 min read
Load More
JOBS